INTEGRA acquires Valdea Biosciences
INTEGRA Biosciences AG has announced that they have signed an agreement to acquire their long time French distribution partner Valdea Biosciences SAS.
The move will maintain all Valdea Biosciences' existing distribution partnerships and provides the resource to help accelerate the launch of INTEGRA's innovative VIAFLO liquid handling tools into the French market.
The acquisition provides for strong mutual benefits. INTEGRA Biosciences will receive direct access to the important French market through Valdea Biosciences sales and service team. Valdea Biosciences in turn will benefit from the stability of being part of a strongly growing international organisation.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Léri-Weill_dyschondrosteosis
Scientists successfully test MERS vaccine in monkeys and camels
Devil_facial_tumour_disease
VIAFLO Corporation and INTEGRA Biosciences enter into Strategic Partnership
SEQUENOM Obtains Core Technology Patent in Europe - New Patent Significantly Expands Proprietary Position for MassARRAY(TM) Technology

LipiDiDiet finds long-lasting and broad effects of nutritional intervention in early Alzheimer’s - 20 percent less brain shrinkage in patients who received a nutrient cocktail than in those in the control group
Cardio3 BioSciences Appoints Drs Jan Andersson and Louise Proulx to its Board of Directors
